NCT03058692: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03058692 |
|---|---|
| Title | A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 9, 2018 |
| Completion date | Jan. 14, 2019 |
| Required reporting date | Jan. 14, 2020, midnight |
| Actual reporting date | Jan. 14, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |